


monitor

MOLECULES

Novel trisubstituted pyrimidines as potential antimalarial agents

Malaria is a tremendous problem for many tropical and subtropical countries. It is caused by several protozoan parasites, namely *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium ovale* and *Plasmodium malariae*, and it is transmitted by female mosquitoes belonging to the *Anopheles* genus. Endemic maps indicate that *P. falciparum* and *P. vivax* account for 95% of malarial infections [1]. Although several antimalarial drugs are available (e.g. quinine, chloroquine, primaquine, cycloguanil, pyrimethamine and proguanil), the parasites develop resistance rapidly. Therefore, the need for new and effective drugs is high. As a part of their ongoing programme in this field, Agarwal and co-workers [2] have previously reported the antimalarial activity of series of triazines, pyrimidines and quinolines. They have synthesized new 2,4,6-trisubstituted pyrimidines [3] that were tested for their

capability to inhibit the maturation (into schizonts) of ring stage *P. falciparum* parasites during a 40 h incubation. Pyrimetamine (**i**) was used as the reference compound.



Series 1: X = CH₃ (methyl group)
 Series 2: X = CH₂C₆H₅ (benzyl group)
 Series 3: X = C₆H₅ (phenyl ring)

The SAR clearly indicates that series **1** (X = CH₃) gives the best derivatives. Substituting the methyl group with a benzyl group (series **2**) slightly reduces the activity and substitution with a phenyl ring (series **3**) is detrimental. As far as the phenyl ring on the pyrimidine moiety is concerned (R),

disubstitution at positions 3 and 4 or 2 and 5 gave the best results. By contrast, trisubstitution did not favour the activity. In particular, minimum inhibitory concentrations (MICs) of 0.5 µg/ml were seen with compounds **1d** and **1f**. In addition, nine compounds had MICs of 1 µg/ml, whereas ten compounds had MICs of 2 µg/ml. In the same test, the MIC for pyrimethamine was 10 µg/ml. On these bases, the new compounds could be considered as leads for antimalarial chemotherapy.

- 1 Kumar, A. (2003) Perspective in antimalarial chemotherapy. *Curr. Med. Chem.* 10, 1137–1150
- 2 Agarwal, A. *et al.* (2005) Synthesis of 2,4,6-trisubstituted triazines as antimalarial agents. *Bioorg. Med. Chem. Lett.* 15, 531–533
- 3 Agarwal, A. *et al.* (2005) Antimalarial activity and synthesis of new trisubstituted pyrimidines. *Bioorg. Med. Chem. Lett.* 15, 3130–3132

Daniela Barlocco
daniela.barlocco@unimi.it

PII: S1359-6446(05)03649-4